跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
5T4-5T4-CD3
首页
药物
5T4-5T4-CD3
5T4-5T4-CD3
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTIBODIES
US 2020277397 A1
申请人: GENMAB AS
优先权: 2018
CN
EP
US
WO
12 件公开
FUSION PROTEIN
EP 4549572 A1
申请人: CHIOME BIOSCIENCE INC
优先权: 2022
CN
EP
US
WO
4 件公开
Fusion protein comprising three binding domains to 5T4 and CD3
US 10941207 B2
申请人: BIOTECNOL LTD
优先权: 2014
CN
US
2 件公开
METHOD FOR TREATING TUMOR WITH COMBINATION OF RECOMBINANT ONCOLYTIC VIRUS AND MACROMOLECULAR ANTIBODY-BASED ANTI-CANCER DRUG
WO 2025112755 A1
申请人: JOINT BIOSCIENCES SH LTD
优先权: 2023
CN
WO
2 件公开
Method of treating cancer by administering an antibody which binds to 5T4
US 12674001 B2
申请人: GENMAB AS
优先权: 2020
US
Chimeric antigen receptor T cell interfered by LRIG1 gene and application of chimeric antigen receptor T cell
CN 121427836 A
申请人: SHANGHAI ENTIBAIAO PHARMACEUTICAL TECH CO LTD
优先权: 2025
CN
药物
反馈